Recent Advances in Understanding the Cellular Functions of BRCA1

  • Ellen Solomon
  • Joanna R. Morris
Part of the Cancer Genetics book series (CANGENETICS)

The first breast and ovarian cancer predisposition gene, BRCA1, was cloned over 14 years ago. The features of BRCA1-defective cells and tumours have been well described; these display genomic instability and multiple centrosomes, are sensitive to DNA-damaging agents that rely on homologous recombination (HR) for repair and the tumours are of a particular pathological subtype (known as basal). Yet the precise molecular defect downstream of BRCA1 loss-of-function remains elusive. More than 70 BRCA1-interacting proteins have been described and in this review we will attempt to draw together recent findings about BRCA1 complexes and activity that inform our current understanding of the cellular tumour suppressor function of BRCA1.


Ring Domain BRCA1 Carrier Centrosome Amplification RAD51 Focus Ubiquitin Conjugate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pujana, M. A., et al. (2007). Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39(11): 1338–49.PubMedGoogle Scholar
  2. 2.
    Grantham, R. (1974). Amino acid difference formula to help explain protein evolution. Science 185(4154): 862–4.PubMedGoogle Scholar
  3. 3.
    Orelli, B. J., et al. (2001). Nine novel conserved motifs in BRCA1 identified by the chicken orthologue. Oncogene 20(32): 4433–8.PubMedGoogle Scholar
  4. 4.
    Mark, W. Y., et al. (2005). Characterization of segments from the central region of BRCA1: an intrinsically disordered scaffold for multiple protein–protein and protein–DNA interactions? J Mol Biol 345(2): 275–87.PubMedGoogle Scholar
  5. 5.
    Boulton, S. J., et al. (2004). BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans. Curr Biol 14(1): 33–9.PubMedGoogle Scholar
  6. 6.
    Xu, X., et al. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22(1): 37–43.PubMedGoogle Scholar
  7. 7.
    Williams, R. S., et al. (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol 8(10): 838–42.PubMedGoogle Scholar
  8. 8.
    Manke, I. A., et al. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302(5645): 636–9.PubMedGoogle Scholar
  9. 9.
    Yu, X., et al. (2003). The BRCT domain is a phospho-protein binding domain. Science 302(5645): 639–42.PubMedGoogle Scholar
  10. 10.
    Williams, R. S., et al. (2004). Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11(6): 519–25.PubMedGoogle Scholar
  11. 11.
    Glover, J. N. (2006). Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer 5(1): 89–93.PubMedGoogle Scholar
  12. 12.
    Clapperton, J. A., et al. (2004). Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11(6): 512–8.PubMedGoogle Scholar
  13. 13.
    Yu, X., et al. (2006). BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 20(13): 1721–6.PubMedGoogle Scholar
  14. 14.
    Kim, H., et al. (2007). Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316(5828): 1202–5.PubMedGoogle Scholar
  15. 15.
    Kim, H., et al. (2007). CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. Nat Struct Mol Biol 14(8): 710–5.PubMedGoogle Scholar
  16. 16.
    Wang, B., et al. (2007). Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316(5828): 1194–8.PubMedGoogle Scholar
  17. 17.
    Ray, H., et al. (2006). ACCA phosphopeptide recognition by the BRCT repeats of BRCA1. J Mol Biol 359(4): 973–82.PubMedGoogle Scholar
  18. 18.
    Shen, Y., et al. (2008). Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. Biochemistry 47(21): 5767–73.PubMedGoogle Scholar
  19. 19.
    Zhong, Q., et al. (1999). Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285(5428): 747–50.PubMedGoogle Scholar
  20. 20.
    Yu, X., et al. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 24(21): 9478–86.PubMedGoogle Scholar
  21. 21.
    Greenberg, R. A., et al. (2006). Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20(1): 34–46.PubMedGoogle Scholar
  22. 22.
    Bekker-Jensen, S., et al. (2006). Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 173(2): 195–206.PubMedGoogle Scholar
  23. 23.
    Au, W. W., et al. (2005). The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci. J Biol Chem 280(8): 6993–7001.PubMedGoogle Scholar
  24. 24.
    Weaver, Z., et al. (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21(33): 5097–107.PubMedGoogle Scholar
  25. 25.
    van Beers, E. H., et al. (2005). Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65(3): 822–7.PubMedGoogle Scholar
  26. 26.
    Liu, X., et al. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104(29): 12111–6.PubMedGoogle Scholar
  27. 27.
    Bryant, H. E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035): 913–7.PubMedGoogle Scholar
  28. 28.
    Farmer, H., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035): 917–21.PubMedGoogle Scholar
  29. 29.
    Quinn, J. E., et al. (2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63(19): 6221–8.PubMedGoogle Scholar
  30. 30.
    Tassone, P., et al. (2003). BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88(8): 1285–91.PubMedGoogle Scholar
  31. 31.
    Quinn, J. E., et al. (2007). BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13(24): 7413–20.PubMedGoogle Scholar
  32. 32.
    Swisher, E. M., et al. (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68(8): 2581–6.PubMedGoogle Scholar
  33. 33.
    Sobhian, B., et al. (2007). RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316(5828): 1198–202.PubMedGoogle Scholar
  34. 34.
    Wang, B., et al. (2007). Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA 104(52): 20759–63.PubMedGoogle Scholar
  35. 35.
    Huen, M. S., et al. (2007). RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131(5): 901–14.PubMedGoogle Scholar
  36. 36.
    Kolas, N. K., et al. (2007). Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318(5856): 1637–40.PubMedGoogle Scholar
  37. 37.
    Mailand, N., et al. (2007). RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131(5): 887–900.PubMedGoogle Scholar
  38. 38.
    Zhao, G. Y., et al. (2007). A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell 25(5): 663–75.PubMedGoogle Scholar
  39. 39.
    Greenberg, R. A. (2008). Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma.Google Scholar
  40. 40.
    Kim, H., et al. (2008). New players in the BRCA1-mediated DNA damage responsive pathway. Mol Cells 25(4): 451–61.Google Scholar
  41. 41.
    Yan, J., et al. (2008). RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett 271(2): 179–90.PubMedGoogle Scholar
  42. 42.
    Gudmundsdottir, K., et al. (2007). The proteasome is involved in determining differential utilization of double-strand break repair pathways. Oncogene 26(54): 7601–6.PubMedGoogle Scholar
  43. 43.
    Jacquemont, C., et al. (2007). Proteasome function is required for DNA damage response and Fanconi anemia pathway activation. Cancer Res 67(15): 7395–405.PubMedGoogle Scholar
  44. 44.
    Hill, D. A., et al. (2004). BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2. J Cell Biochem 91(5): 987–98.PubMedGoogle Scholar
  45. 45.
    Penkner, A., et al. (2007). A conserved function for a Caenorhabditis elegans Com1/Sae2/CtIP protein homolog in meiotic recombination. EMBO J 26(24): 5071–82.PubMedGoogle Scholar
  46. 46.
    Sartori, A. A., et al. (2007). Human CtIP promotes DNA end resection. Nature 450(7169): 509–14.PubMedGoogle Scholar
  47. 47.
    Takeda, S., et al. (2007). Ctp1/CtIP and the MRN complex collaborate in the initial steps of homologous recombination. Mol Cell 28(3): 351–2.PubMedGoogle Scholar
  48. 48.
    Moynahan, M. E., et al. (1999). Brca1 controls homology-directed DNA repair. Mol Cell 4(4): 511–8.PubMedGoogle Scholar
  49. 49.
    Cousineau, I., et al. (2005). BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res 65(24): 11384–91.PubMedGoogle Scholar
  50. 50.
    Zhou, C., et al. (2005). The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun 336(3): 952–60.PubMedGoogle Scholar
  51. 51.
    Schlegel, B. P., et al. (2006). BRCA1 promotes induction of ssDNA by ionizing radiation. Cancer Res 66(10): 5181–9.PubMedGoogle Scholar
  52. 52.
    Huber, L. J., et al. (2001). Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol Cell Biol 21(12): 4005–15.PubMedGoogle Scholar
  53. 53.
    Yun, J., et al. (2005). Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 24(25): 4009–16.PubMedGoogle Scholar
  54. 54.
    Martin, R. W., et al. (2007). RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67(20): 9658–65.PubMedGoogle Scholar
  55. 55.
    Klein, H. L. (2008). The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 7(5): 686–93.Google Scholar
  56. 56.
    Youds, J. L., et al. (2008). DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair. Mol Cell Biol 28(5): 1470–9.PubMedGoogle Scholar
  57. 57.
    Kruisselbrink, E., et al. (2008). Mutagenic capacity of endogenous G4 DNA underlies genome instability in FANCJ-defective C. elegans. Curr Biol 18(12): 900–5.PubMedGoogle Scholar
  58. 58.
    Zhao, Y., et al. (2008). Spectrum of mutational events in the absence of DOG-1/FANCJ in Caenorhabditis elegans. DNA Repair (Amst).Google Scholar
  59. 59.
    Wu, Y., et al. (2008). FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability. Mol Cell Biol 28(12): 4116–28.PubMedGoogle Scholar
  60. 60.
    Kumaraswamy, E., et al. (2007). Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol Cell Biol 27(19): 6733–41.PubMedGoogle Scholar
  61. 61.
    Peng, M., et al. (2007). The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J 26(13): 3238–49.PubMedGoogle Scholar
  62. 62.
    Paull, T. T., et al. (2001). Direct DNA binding by Brca1. Proc Natl Acad Sci USA 98(11): 6086–91.PubMedGoogle Scholar
  63. 63.
    Naseem, R., et al. (2008). Analysis of the DNA binding activity of BRCA1 and its modulation by the tumour suppressor p53. PLoS ONE 3(6): e2336.PubMedGoogle Scholar
  64. 64.
    Swinnen, J. V., et al. (2006). Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9(4): 358–65.PubMedGoogle Scholar
  65. 65.
    Moreau, K., et al. (2006). BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281(6): 3172–81.PubMedGoogle Scholar
  66. 66.
    Brunet, J., et al. (2008). BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 47(2): 157–63.PubMedGoogle Scholar
  67. 67.
    Lorick, K. L., et al. (1999). RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 96(20): 11364–9.PubMedGoogle Scholar
  68. 68.
    Brzovic, P. S., et al. (2003). Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 100(10): 5646–51.PubMedGoogle Scholar
  69. 69.
    Hashizume, R., et al. (2001). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276(18): 14537–40.PubMedGoogle Scholar
  70. 70.
    Xia, Y., et al. (2003). Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 278(7): 5255–63.PubMedGoogle Scholar
  71. 71.
    Morris, J. R., et al. (2006). Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 15(4): 599–606.PubMedGoogle Scholar
  72. 72.
    Morris, J. R., et al. (2004). BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 13(8): 807–17.PubMedGoogle Scholar
  73. 73.
    Polanowska, J., et al. (2006). A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J 25(10): 2178–88.PubMedGoogle Scholar
  74. 74.
    Nishikawa, H., et al. (2003). Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem.Google Scholar
  75. 75.
    Wu-Baer, F., et al. (2003). The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 278(37): 34743–6.PubMedGoogle Scholar
  76. 76.
    Peng, J., et al. (2003). A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 21(8): 921–6.PubMedGoogle Scholar
  77. 77.
    Meierhofer, D., et al. (2008). Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry. J Proteome Res 7(10): 4566–76.PubMedGoogle Scholar
  78. 78.
    Lam, Y. A., et al. (1997). Specificity of the ubiquitin isopeptidase in the PA700 regulatory complex of 26 S proteasomes. J Biol Chem 272(45): 28438–46.PubMedGoogle Scholar
  79. 79.
    Ben-Saadon, R., et al. (2006). The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 24(5): 701–11.PubMedGoogle Scholar
  80. 80.
    Mallery, D. L., et al. (2002). Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 21(24): 6755–62.PubMedGoogle Scholar
  81. 81.
    Brzovic, P. S., et al. (2006). A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination. Mol Cell 21(6): 873–80.PubMedGoogle Scholar
  82. 82.
    Christensen, D. E., et al. (2007). E2–BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat Struct Mol Biol 14(10): 941–8.PubMedGoogle Scholar
  83. 83.
    Chappuis, P. O., et al. (2005). Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 16(5): 735–42.PubMedGoogle Scholar
  84. 84.
    Aaltonen, K., et al. (2008). Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 14(7): 1976–83.PubMedGoogle Scholar
  85. 85.
    Fukasawa, K. (2007). Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 7(12): 911–24.PubMedGoogle Scholar
  86. 86.
    Hsu, L. C., et al. (1998). BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 95(22): 12983–8.PubMedGoogle Scholar
  87. 87.
    Parvin, J. D., et al. (2006). The BRCA1 E3 ubiquitin ligase controls centrosome dynamics. Cell Cycle 5(17): 1946–50.PubMedGoogle Scholar
  88. 88.
    Sato, K., et al. (2004). Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem 279(30): 30919–22.PubMedGoogle Scholar
  89. 89.
    Joukov, V., et al. (2006). The BRCA1/BARD1 heterodimer modulates Ran-dependent mitotic spindle assembly. Cell 127(3): 539–52.PubMedGoogle Scholar
  90. 90.
    Hamilton, S. R., et al. (2007). The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282(22): 16667–80.PubMedGoogle Scholar
  91. 91.
    Zlobec, I., et al. (2008). Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 57(10): 1413–9.PubMedGoogle Scholar
  92. 92.
    Schmitt, M., et al. (2008). RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111(3): 1357–65.PubMedGoogle Scholar
  93. 93.
    Crainie, M., et al. (1999). Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 93(5): 1684–96.PubMedGoogle Scholar
  94. 94.
    Fedier, A., et al. (2003). The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 22(5): 1169–73.PubMedGoogle Scholar
  95. 95.
    Chabalier, C., et al. (2006). BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5(9): 1001–7.PubMedGoogle Scholar
  96. 96.
    Scully, R., et al. (1997). BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 94(11): 5605–10.PubMedGoogle Scholar
  97. 97.
    Anderson, S. F., et al. (1998). BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 19(3): 254–6.PubMedGoogle Scholar
  98. 98.
    Schlegel, B. P., et al. (2000). BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. Proc Natl Acad Sci USA 97(7): 3148–53.PubMedGoogle Scholar
  99. 99.
    Krum, S. A., et al. (2003). BRCA1 associates with processive RNA polymerase II. J Biol Chem 278(52): 52012–20.PubMedGoogle Scholar
  100. 100.
    Chiba, N., et al. (2002). The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Res 62(15): 4222–8.PubMedGoogle Scholar
  101. 101.
    Starita, L. M., et al. (2005). BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 280(26): 24498–505.PubMedGoogle Scholar
  102. 102.
    Murray, M. M., et al. (2007). Role played by BRCA1 in transcriptional regulation in response to therapy. Biochem Soc Trans 35(Pt 5): 1342–6.PubMedGoogle Scholar
  103. 103.
    Horwitz, A. A., et al. (2007). A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase. Proc Natl Acad Sci USA 104(16): 6614–9.PubMedGoogle Scholar
  104. 104.
    Fabbro, M., et al. (2008). BARD1 regulates BRCA1-mediated transactivation of the p21WAF1/CIP1 and Gadd45 promoters. Cancer Lett 263(2): 189–96.PubMedGoogle Scholar
  105. 105.
    Wu, W., et al. (2007). BRCA1 ubiquitinates RPB8 in response to DNA damage. Cancer Res 67(3): 951–8.PubMedGoogle Scholar
  106. 106.
    Press, J. Z., et al. (2008). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17.PubMedGoogle Scholar
  107. 107.
    Hosey, A. M., et al. (2007). Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99(22): 1683–94.PubMedGoogle Scholar
  108. 108.
    Lusa, L., et al. (2008). Re: molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 100(10): 752–3; author reply 753–4.PubMedGoogle Scholar
  109. 109.
    Honeth, G., et al. (2008). CD44+/CD24– phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3): R53.PubMedGoogle Scholar
  110. 110.
    Smalley, M. J., et al. (2008). BRCA1 and stem cells: tumour typecasting. Nat Cell Biol 10(4): 377–9.PubMedGoogle Scholar
  111. 111.
    Wicha, M. S. (2008). Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 10(2): 105.PubMedGoogle Scholar
  112. 112.
    Wright, M. H., et al. (2008). Brca1 breast tumors contain distinct CD44+/CD24– and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1): R10.PubMedGoogle Scholar
  113. 113.
    Eakin, C. M., et al. (2007). Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 104(14): 5794–9.PubMedGoogle Scholar
  114. 114.
    Poole, A. J., et al. (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804): 1467–70.PubMedGoogle Scholar
  115. 115.
    Prokopcova, J., et al. (2007). The role of ATM in breast cancer development. Breast Cancer Res Treat 104(2): 121–8.PubMedGoogle Scholar
  116. 116.
    Durocher, F., et al. (2006). Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6: 230.PubMedGoogle Scholar
  117. 117.
    Seal, S., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11): 1239–41.PubMedGoogle Scholar
  118. 118.
    De Nicolo, A., et al. (2008). A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res 14(14): 4672–80.PubMedGoogle Scholar
  119. 119.
    Guenard, F., et al. (2008). Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet 53(7): 579–91.PubMedGoogle Scholar
  120. 120.
    Balogh, G. A., et al. (2006). The mismatch repair gene hPMS2 is mutated in primary breast cancer. Int J Mol Med 18(5): 853–7.PubMedGoogle Scholar
  121. 121.
    Geary, J., et al. (2008). Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7(2): 163–72.PubMedGoogle Scholar
  122. 122.
    Akbari, M. R., et al. (2008). Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Res Treat.Google Scholar
  123. 123.
    Novak, D. J., et al. (2008). Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases. Breast Cancer Res Treat.Google Scholar
  124. 124.
    Osorio, A., et al. (2008). Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat.Google Scholar
  125. 125.
    Gorringe, K. L., et al. (2007). Breast cancer risk and the BRCA1 interacting protein CTIP. Breast Cancer Res Treat.Google Scholar
  126. 126.
    Wu, M., et al. (2007). CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer. Mol Cancer Res 5(12): 1285–95.PubMedGoogle Scholar
  127. 127.
    Joukov, V., et al. (2001). Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development. Proc Natl Acad Sci USA 98(21): 12078–83.PubMedGoogle Scholar
  128. 128.
    McCarthy, E. E., et al. (2003). Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol 23(14): 5056–63.PubMedGoogle Scholar
  129. 129.
    Thai, T. H., et al. (1998). Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7(2): 195–202.PubMedGoogle Scholar
  130. 130.
    Ishitobi, M., et al. (2003). Mutational analysis of BARD1 in familial breast cancer patients in Japan. Cancer Lett 200(1): 1–7.PubMedGoogle Scholar
  131. 131.
    Karppinen, S. M., et al. (2006). Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet 43(11): 856–62.PubMedGoogle Scholar
  132. 132.
    Vahteristo, P., et al. (2006). BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. Eur J Hum Genet 14(2): 167–72.PubMedGoogle Scholar
  133. 133.
    Huo, X., et al. (2007). Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case–control analysis. Breast Cancer Res Treat 102(3): 329–37.PubMedGoogle Scholar
  134. 134.
    Jakubowska, A., et al. (2007). BARD1 and breast cancer in Poland. Breast Cancer Res Treat.Google Scholar
  135. 135.
    Jensen, J. P., et al. (1995). Identification of a family of closely related human ubiquitin conjugating enzymes. J Biol Chem 270(51): 30408–14.PubMedGoogle Scholar
  136. 136.
    Perrin-Vidoz, L., et al. (2002). The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11(23): 2805–14.PubMedGoogle Scholar
  137. 137.
    Anczukow, O., et al. (2007). Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ellen Solomon
    • 1
  • Joanna R. Morris
    • 1
  1. 1.Cancer Genetics Laboratory, Department of Medical and Molecular Genetics, and Breakthrough Breast Cancer Research UnitKing’s College Medical School, Guy’s HospitalLondonUK

Personalised recommendations